All‐cause mortality · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (deaths) Â · COPD and at least one other long‐term condition
It is very uncertain whether intervention changes all‐cause mortality (deaths) Â compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with CKD
1 finding from 1 review
All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with chronic obstructive pulmonary disease
It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes mortality (all‐cause) overall analysis compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · beta blockers
Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)
Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).
1 finding from 1 review
All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)
It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people at increased risk for developing type 2 diabetes
It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality within 3 months · people with acute ischemic stroke
Thrombo‐aspiration alone showed no clear difference in all‐cause mortality within 3 months compared with stent‐retrieval thrombectomy alone (high certainty).
1 finding from 1 review
All‐cause mortality
It is very uncertain whether summary of findings: Comparison 1 ‐ deferiprone (DFP) changes all‐cause mortality compared with deferoxamine (DFO) (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review
All‐cause mortality
1 finding from 1 review